All In Biotech

Investigational drug · Phase 2

GSK3528869A

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Hepatitis B, Chronic.

Phase 2

Last checked: Nov 20, 2026Latest source record: Dec 30, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

1

0 still active

All registered trials

2

Any phase or sponsor naming "GSK3528869A"

First trial start

2022

Mar 22, 2022

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "GSK3528869A", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Hepatitis B, Chronic

Approved drugs for the same conditions: Hepatitis B · Infectious disease and vaccines

Largest trials

Live from ClinicalTrials.gov: studies naming "GSK3528869A" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 0 on PubMed

No PubMed records name it yet, which is common for early code-named drugs.

Also in development for Hepatitis B, Chronic

  • ElebsiranVIR-2218, BRII-835Phase 38 trials

    Vir Biotechnology, Inc. · Viral Hepatitis, Hepatitis D, Chronic, Chronic Hepatitis B Virus (HBV) Infection

  • VIR-3434TobevibartPhase 35 trials

    Vir Biotechnology, Inc. · Viral Hepatitis, Hepatitis D, Chronic, Hepatitis B, Chronic

  • Peg-IFN-αpegylated interferonPhase 26 trials

    Brii Biosciences Limited · Chronic Hepatitis B, Chronic Hepatitis B Virus (HBV) Infection, Hepatitis B, Chronic

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from GSK.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.